Progression of Corpus Callosum Atrophy in Alzheimer Disease

Abstract

Measurement of corpus callosum size allows in vivo mapping of neocortical neurodegeneration in AD over a wide range of clinical dementia severities and may be used as a surrogate marker for evaluation of drug efficacy.